The global advanced drug delivery market was valued at $44,029.59 million in 2020, and is estimated to reach $1,95,132.45 million by 2030, growing at a CAGR of 16.0% from 2021 to 2030. Advanced drug delivery is an improved method for delivering the drug molecule to the targeted site in a more controlled manner. Advance drug delivery systems are based on novel drug delivery techniques and utilize the most advanced technologies. They are intended to administer the medicine in a regulated or modulated manner within the tissue or cells, with the goal of providing safe and effective therapy.
The advanced drug delivery system comprises oral, parenteral, pulmonary, transmucosal, transdermal, carrier based systems like nanoparticles, nanospheres, nanocapsules, nanoemulsions, and nano-sized vesicular carriers, such as liposomes, niosomes, dendrimers, and polymeric or lipid-based carriers and other drug delivery systems. These advanced drug delivery technologies have the potential to overcome the limitations of the already existing drugs. Various factors, such as pharmacodynamics, drug toxicity, immunogenicity, bio compatibility, pharmacokinetics, and drug efficacy, are considered while developing advanced drug delivery systems.
The primary goal of adopting advanced drug delivery (ADD) is not only to deliver a biologically active molecule in a regulated way (time, period and releasing rate), but also to keep drug levels in the body within the therapeutic window. Furthermore, the drug can be directed toward a specific organ or tissue (targeted drug delivery).
They assist in the delivery of medication levels in the body by minimizing toxicity and effectively delivering the drug at the intended location of the action. The key benefit of ADD is its flexibility and potential to increase drug bioavailability. Drug therapeutic efficacy and safety profiles can be enhanced by more accurate spatial and temporal placement in the body, resulting in lower dosage frequency. These techniques are being developed to improve the efficacy ratio of currently available medications. The development of advanced drug delivery systems is based on the delivery of drugs at a controlled pace, as well as slow and targeted distribution for onsite drug release and absorption.
The growth of advanced drug delivery market is majorly driven by the rise in the prevalence of chronic diseases. Chronic diseases are described generally as problems that persist a year or longer and need continuous medical treatment, that limit everyday activities, or both.
According to the Center of Disease Control and Prevention (CDC) in 2020, every year, more than 868,000 Americans succumb to heart disease, stroke, or other cardiovascular disorders, accounting for one-third of all deaths in the U.S. 6 out of 10 Americans have at least one chronic condition, and 4 out of 10 have two or more heart, stroke, cancer, or diabetes. These and other chronic diseases are the leading causes of death and disability in the U.S. and they are also a leading driver of healthcare costs. These diseases also take an economic toll, costing $214 billion a year to the health care system and causing $138 billion in lost productivity from premature death alone. They are also major contributors to the country's $3.8 trillion in yearly health-care expenses. Thus, the rise in chronic diseases leads to the surge in demand for advanced drug delivery for safe and effective therapy.
In addition, the market is driven by advancements as well as R&D activities in understanding of human biology and diseases leading to the development of new drugs and biologics. For instance, in December 2019, researchers at the Massachusetts Institute of Technology (MIT) have developed a microneedle platform that uses quantum dots (QD), which are fluorescent microparticles that can deliver vaccines while also invisibly encoding vaccination history in the skin. The quantum dots are made up of nanocrystals that emit near-infrared light that may be detected by a smartphone with a specific sensor. Thus, such developments significantly boost the advanced drug delivery market.
However, rise in the number of drug recalls and drug failures of advanced drug delivery, challenges in nanomedicine based drug delivery are expected to hamper the market growth. For instance, according to the USFDA’s Center for Drug Evaluation and Research (CDER) in 2020 about 53 new molecular entities (NMEs) were approved. Thus, the rise in such drug approvals and innovations further drive the market for designing various advanced drug delivery systems. Furthermore, an increase in R&D spending and surge in healthcare expenditure worldwide, specifically in the developing economies leads to an increased demand for advanced drug delivery products for better efficacy and thus, is a great opportunity for the key players of the market for investment.
The global advanced drug delivery market is segmented on the basis of product type, end user, and region. On the basis of product type, the market is segregated into drug eluting lens, microneedle patch, hydrogel drug delivery and nano carrier. By end user, it is fragmented into hospitals, specialized clinics and others. On the basis of region, the market is analyzed across North America, Europe, Asia-Pacific and LAMEA.
The major players profiled in the report are Alnylam Pharmaceuticals Inc., Altaris Capital Partners Llc. (Kindeva Drug Delivery), Bausch Health Companies Inc., (Bausch & Lomb), Biogen Limited, Endo International Plc., Johnson & Johnson (Johnson & Johnson Vision), Micropoint Technologies, Novo Nordisk A/S, Ocular Therapeutix Inc. and Takeda Pharmaceutical Company Limited.
The advanced drug delivery system comprises oral, parenteral, pulmonary, transmucosal, transdermal, carrier based systems like nanoparticles, nanospheres, nanocapsules, nanoemulsions, and nano-sized vesicular carriers, such as liposomes, niosomes, dendrimers, and polymeric or lipid-based carriers and other drug delivery systems. These advanced drug delivery technologies have the potential to overcome the limitations of the already existing drugs. Various factors, such as pharmacodynamics, drug toxicity, immunogenicity, bio compatibility, pharmacokinetics, and drug efficacy, are considered while developing advanced drug delivery systems.
The primary goal of adopting advanced drug delivery (ADD) is not only to deliver a biologically active molecule in a regulated way (time, period and releasing rate), but also to keep drug levels in the body within the therapeutic window. Furthermore, the drug can be directed toward a specific organ or tissue (targeted drug delivery).
They assist in the delivery of medication levels in the body by minimizing toxicity and effectively delivering the drug at the intended location of the action. The key benefit of ADD is its flexibility and potential to increase drug bioavailability. Drug therapeutic efficacy and safety profiles can be enhanced by more accurate spatial and temporal placement in the body, resulting in lower dosage frequency. These techniques are being developed to improve the efficacy ratio of currently available medications. The development of advanced drug delivery systems is based on the delivery of drugs at a controlled pace, as well as slow and targeted distribution for onsite drug release and absorption.
The growth of advanced drug delivery market is majorly driven by the rise in the prevalence of chronic diseases. Chronic diseases are described generally as problems that persist a year or longer and need continuous medical treatment, that limit everyday activities, or both.
According to the Center of Disease Control and Prevention (CDC) in 2020, every year, more than 868,000 Americans succumb to heart disease, stroke, or other cardiovascular disorders, accounting for one-third of all deaths in the U.S. 6 out of 10 Americans have at least one chronic condition, and 4 out of 10 have two or more heart, stroke, cancer, or diabetes. These and other chronic diseases are the leading causes of death and disability in the U.S. and they are also a leading driver of healthcare costs. These diseases also take an economic toll, costing $214 billion a year to the health care system and causing $138 billion in lost productivity from premature death alone. They are also major contributors to the country's $3.8 trillion in yearly health-care expenses. Thus, the rise in chronic diseases leads to the surge in demand for advanced drug delivery for safe and effective therapy.
In addition, the market is driven by advancements as well as R&D activities in understanding of human biology and diseases leading to the development of new drugs and biologics. For instance, in December 2019, researchers at the Massachusetts Institute of Technology (MIT) have developed a microneedle platform that uses quantum dots (QD), which are fluorescent microparticles that can deliver vaccines while also invisibly encoding vaccination history in the skin. The quantum dots are made up of nanocrystals that emit near-infrared light that may be detected by a smartphone with a specific sensor. Thus, such developments significantly boost the advanced drug delivery market.
However, rise in the number of drug recalls and drug failures of advanced drug delivery, challenges in nanomedicine based drug delivery are expected to hamper the market growth. For instance, according to the USFDA’s Center for Drug Evaluation and Research (CDER) in 2020 about 53 new molecular entities (NMEs) were approved. Thus, the rise in such drug approvals and innovations further drive the market for designing various advanced drug delivery systems. Furthermore, an increase in R&D spending and surge in healthcare expenditure worldwide, specifically in the developing economies leads to an increased demand for advanced drug delivery products for better efficacy and thus, is a great opportunity for the key players of the market for investment.
The global advanced drug delivery market is segmented on the basis of product type, end user, and region. On the basis of product type, the market is segregated into drug eluting lens, microneedle patch, hydrogel drug delivery and nano carrier. By end user, it is fragmented into hospitals, specialized clinics and others. On the basis of region, the market is analyzed across North America, Europe, Asia-Pacific and LAMEA.
The major players profiled in the report are Alnylam Pharmaceuticals Inc., Altaris Capital Partners Llc. (Kindeva Drug Delivery), Bausch Health Companies Inc., (Bausch & Lomb), Biogen Limited, Endo International Plc., Johnson & Johnson (Johnson & Johnson Vision), Micropoint Technologies, Novo Nordisk A/S, Ocular Therapeutix Inc. and Takeda Pharmaceutical Company Limited.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides an extensive analysis of the current and emerging market trends and dynamics in the global advanced drug delivery market to identify the prevailing opportunities.
- This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
- Comprehensive analysis of factors that drive and restrict the market growth is provided.
- Region- & country-wise analysis is provided to understand the market trends and dynamics.
KEY MARKET SEGMENTS
By Product Type
- Drug eluting lens
- Microneedle patch
- Hydrogel drug delivery
- Nano carrier
By End User
- Hospitals
- Specialized clinics
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
KEY MARKET PLAYERS
- Alnylam Pharmaceuticals Inc.
- Altaris Capital Partners Llc. (Kindeva Drug Delivery)
- Bausch Health Companies Inc., (Bausch & Lomb)
- Biogen Limited
- Endo International Plc.
- Johnson & Johnson (Johnson & Johnson Vision)
- Micropoint Technologies
- Novo Nordisk A/S
- Ocular Therapeutix Inc.
- Takeda Pharmaceutical Company Limited
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET LANDSCAPE
CHAPTER 4: ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE
CHAPTER 5: ADVANCED DRUG DELIVERY MARKET, BY END USER
CHAPTER 6: ADVANCED DRUG DELIVERY MARKET, BY REGION
CHAPTER 7: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Alnylam Pharmaceuticals Inc.
- Altaris Capital Partners Llc. (Kindeva Drug Delivery)
- Bausch Health Companies Inc.
- (Bausch & Lomb)
- Biogen Limited
- Endo International Plc
- Johnson & Johnson (Johnson & Johnson Vision)
- Micropoint Technologies
- Novo Nordisk A/S
- Cular Therapeutix Inc.
- Takeda Pharmaceutical Company Limited.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 190 |
| Published | December 2021 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 44029.59 million |
| Forecasted Market Value ( USD | $ 195132.45 million |
| Compound Annual Growth Rate | 16.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
